News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selecta Biosciences, Inc. Announces Allowance Of The First In A Series Of Patents On The Induction Of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies


12/9/2013 9:15:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that the US Patent and Trademark Office (USPTO) has allowed the issuance of a Selecta owned patent with the title “Tolerogenic Synthetic Nanocarriers For Inducing Regulatory B Cells”, the first in a series of patent filings on antigen-specific tolerogenic immunotherapies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES